SPPAM
AKRO icon

Summit Partners Public Asset Management’s Akero Therapeutics AKRO Stock Holding History

Summit Partners Public Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-377,152
Closed -$17.9M – 131
2025
Q3 		$17.9M Buy
377,152
+10,155
+3% +$492K 0.37% 74
2025
Q2 		$19.6M Sell
366,997
-213,003
-37% -$9.68M 0.5% 63
2025
Q1 		$23.5M Buy
+580,000
New +$24.6M 0.6% 60

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Summit Partners Public Asset Management's AKRO Position: Q4 2025 in Review

Summit Partners Public Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 377,152 shares — an estimated $17.9M sold.

Summit Partners Public Asset Management first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $23.5M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Summit Partners Public Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 377,152 Akero Therapeutics shares in Q4 2025, an estimated $17.9M.
  • Summit Partners Public Asset Management first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
  • Summit Partners Public Asset Management's Akero Therapeutics position peaked at $23.5M in Q1 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.